Cannabis Tax Uncertainty Persists After Rescheduling

Photo by cottonbro studio via Pexels.

Picture a dispensary owner opening the spreadsheet for next quarter's estimated taxes. One line item, the tax bill driven by Section 280E, might be much smaller than it was last year, or it might not. The rules may have moved, but the guidance that explains how to apply them is hard to find.

The catalyst is a reported federal move on April 28, 2026, shifting marijuana held under a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act. Tax advisors care because 280E turns on the schedule. Change the schedule and the penalty may change with it.

This article separates what has been reported from what is still unconfirmed. Much of it rests on one law firm's account, not on primary government documents. Nothing here is legal or tax advice, and anyone making filing decisions should confirm the details with a qualified professional.

What Actually Changed on April 28

A tax-law practice blog dated October 18, 2026, by Venar Ayar, JD, LLM (Tax), states that marijuana held under a state medical marijuana license moved from Schedule I to Schedule III of the Controlled Substances Act on April 28, 2026. That is one law firm's description. The Federal Register citation, the exact effective date and the scope of the action still need to be checked at federalregister.gov or dea.gov before anyone treats them as settled.

Scope is the first thing to pin down. The blog's wording points to state-licensed medical marijuana specifically. Whether adult-use product is covered, partly covered or left where it was is not something the available material answers, so operators should not assume it.

The schedule matters because of how the federal tax penalty is built. Businesses dealing in Schedule I or II substances are hit by it. Schedule III substances generally are not. A shift down one tier is therefore a tax event, not merely a regulatory label change.

Federal scheduling also does not rewrite state licensing rules. A medical license in one state comes with its own product limits, patient requirements and reporting duties, and those stay in place regardless of what happens in Washington. Legality and tax treatment vary by state, so confirm the rules in your own jurisdiction.

Where Section 280E Stands Now

Section 280E of the Internal Revenue Code bars businesses that traffic in Schedule I or II substances from deducting ordinary business expenses. Rent, payroll for non-production staff, marketing and utilities have all been exposed to it. Cost of goods sold is still allowed, which is why cannabis accountants spend so much effort on what counts as inventory cost.

The same law firm characterizes the April 2026 rescheduling as meaning 280E no longer reaches state-licensed medical cannabis. Treat that as one firm's reading. It has not been confirmed here against the Federal Register, the DEA or the IRS, and a firm's summary is not a substitute for the text of the action.

If that reading holds, it creates a dividing line. A medical-only operator could be in a very different position from an adult-use-only operator, if adult-use product remains in Schedule I.

Mixed operators face the hardest question. A business with both medical and adult-use sales may have to allocate shared expenses, like rent, salaries and security, between covered and uncovered activity. There is no confirmed method for doing that, and the answer could affect real dollars.

No verified estimates of savings exist in the research behind this piece, so none are offered. The benefit depends on each business's revenue mix, expense structure and state.

The Questions Nobody Has Answered Yet

The most basic gap is whether the IRS or Treasury has issued any guidance on 280E since the reported change. That is unverified. The place to check is irs.gov, and anyone relying on a position should look there directly and note what is and is not published, not take a secondhand account.

The practical questions operators are likely asking are plain enough:

• How does the rule apply to adult-use businesses?
• Is any relief retroactive, and to what date?
• Can prior-year returns be amended, and can refunds be claimed?

The status of any DEA hearing or further rulemaking on broader rescheduling also needs checking. Without confirmed information, speculating on timing would only add noise.

Litigation, congressional bills or executive actions could shift the picture again. Before naming any specific bill, verify it on congress.gov. Citing a bill number from memory or from a blog is how errors spread.

The uncertainty is the real story here. A rule change without clear tax guidance leaves operators making budgeting, hiring and filing decisions on incomplete information, and the cost of guessing wrong falls on them.

How Operators Can Plan While They Wait

Start with a tax professional who works with cannabis clients. The right filing position depends on license type, state and the specific facts of the business, and no general article can settle that. Do not change a filing position on the strength of a headline.

Records are the cheapest protection. Keep medical and adult-use revenue, costs and inventory separated so expenses can be allocated later under whatever guidance emerges. Retrofitting that separation after the fact is expensive and hard to defend.

Budget conservatively. Treat any possible 280E savings as unconfirmed in cash-flow forecasts, and avoid spending money that has not been secured. Ask an advisor about reserving for uncertain tax positions, and about the deadlines and risks involved in amending prior returns.

A short checklist to bring to that conversation:

• Confirm the scope of the April 28, 2026 action in the Federal Register.
• Check irs.gov for any 280E guidance.
• Separate medical and adult-use records going forward.
• Keep projected savings out of committed spending.
• Ask about reserves and amended-return deadlines.
• Confirm your state's rules and tax treatment.

Legality and tax treatment vary by state, so confirm local law before acting.

The headline change may well be real, but whether it helps any given business depends on guidance that has not been confirmed. Decisions about filings and spending should wait for primary sources, meaning the Federal Register, the DEA and the IRS, not law-firm summaries.

The sharper lesson is the split. Federal rescheduling that reaches medical but possibly not adult-use product sorts operators into different tax positions, and mixed businesses sit in the middle. Clean records that separate the two lines are the cheapest hedge, because they hold their value whichever way the rules settle.

Browse our seed collection.